SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Jonathan Weiss/Shutterstock
Drug Development
With Two Wins at SABCS, AstraZeneca Continues Breast Cancer Rally
AstraZeneca posted two mid-stage wins at the 2022 San Antonio Breast Cancer Symposium on Thursday, touting the efficacy of capivasertib and camizestrant against breast cancer.
December 9, 2022
 · 
2 min read
 · 
Tristan Manalac
Chesnot/Getty Images
Business
Sanofi Backs Out of Revolution Partnership in Latest Cancer Cull
Sanofi has terminated its global development and commercialization pact with Revolution Medicines, Inc. for their SHP2 inhibitor drug candidate,
December 8, 2022
 · 
2 min read
 · 
Tristan Manalac
courtesy of Shutterstock
Drug Development
‘Dramatic’ Placebo Effect Trips Relmada’s MDD Hopeful for the Second Time
Relmada’s investigational NDMA receptor channel blocker, REL-1017, failed to meet its primary endpoint in major depressive disorder in the Phase III RELIANCE I trial.
December 8, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy Getty Images
Drug Development
Prometheus’ Anti-TL1A Monoclonal Antibody Notches Wins in Colitis, Crohn’s
Findings from the Phase II ARTEMIS-UC and Phase IIa APOLLO-CD trials show that Prometheus’ PRA023 is potentially safe and effective for treating ulcerative colitis and Crohn’s disease.
December 7, 2022
 · 
2 min read
 · 
Tristan Manalac
Business
Karuna Taps New CEO, Prepares to Submit NDA for Schizophrenia Candidate
Karuna Therapeutics appointed Bill Meury as its new president and chief executive officer, succeeding its current head, Steve Paul.
December 7, 2022
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Gossamer’s PAH Candidate Meets Primary Endpoint, Stumbles on Secondary Measure
Topline results from the Phase II TORREY study showed Gossamer Bio’s seralutinib met its primary efficacy endpoint in pulmonary arterial hypertension.
December 6, 2022
 · 
3 min read
 · 
Tristan Manalac
Business
MEI Abandons PI3K Inhibitor, 30% of Staff in Strategic Shift
MEI Pharma, Inc. will have a strategic realignment that would see at least 30% of its workforce laid off and a pivot towards two of its earlier clinical-stage assets.
December 6, 2022
 · 
2 min read
 · 
Tristan Manalac
male hands with wrist watch is considered American dollars. Hands holding dollar cash. 1000 dollars in 100 bills in a man's hand close-up on a dark background. hundred
Business
SonoThera Bags $60M for Ultrasound-Guided, Non-Viral Gene Therapy
SonoThera closed its Series A round of financing Monday, counting $60.75 million in earnings and will use these proceeds to advance its ultrasound-guided, non-viral gene therapy platform.
December 5, 2022
 · 
2 min read
 · 
Tristan Manalac
Al Drago/CQ Roll Call
Drug Development
FDA Clears First IND for a Multiplex-Base Edited Investigational Therapy
The FDA has lifted its clinical hold on Beam Therapeutics’ BEAM-201 and cleared the way for an Investigational New Drug Application, the company announced Friday.
December 2, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Cristina Arias/Getty Images
Drug Development
Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study (Updated)
Eli Lilly’s investigational antibody donanemab met all of its primary and secondary endpoints in the Phase III TRAILBLAZER-ALZ 4 study, the company announced Wednesday.
December 1, 2022
 · 
3 min read
 · 
Tristan Manalac
PictureDesignSwiss / Shutterstock
Drug Development
Eisai & Biogen Address Lecanemab’s Safety Concerns at CTAD
Full data from the Phase III Clarity AD trial show Eisai and Biogen’s lecanemab has a favorable safety profile in patients with Alzheimer’s disease.
November 30, 2022
 · 
3 min read
 · 
Tristan Manalac
Courtesy of Roland Magnusson/Getty Images
Deals
AstraZeneca Deepens Cancer Cell Therapy Portfolio with Neogene Buyout (Updated)
AstraZeneca and Neogene have entered into a definitive acquisition agreement in which AstraZeneca will buy all outstanding equity in the smaller company.
November 29, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Taljat David/Shutterstock
Policy
FDA Grants Priority Review to Sarepta’s DMD Gene Therapy
The FDA has accepted Sarepta’s BLA for the accelerated approval of SRP-9001, an investigational gene therapy for DMD. Roche is responsible for commercialization outside the U.S.
November 28, 2022
 · 
2 min read
 · 
Tristan Manalac
Benlysta is the first biologic to be approved for
Drug Development
GSK’s Blenrep Exits U.S. Market After Failing Confirmatory Trial (Updated)
Following a request from the FDA, GSK is withdrawing its multiple myeloma drug Blenrep from the U.S. market while continuing to push other combination trial programs.
November 22, 2022
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Lysogene Becomes Latest Company to Fail with AAVs in CNS Disorders (Updated)
Lysogene’s investigational gene therapy LYS-SAF302 failed to meet its primary and key secondary efficacy endpoints in mucopolysaccharidosis type IIIA.
November 21, 2022
 · 
3 min read
 · 
Tristan Manalac
Load More